ArticleJournal of medical primatology2026
The Potency of Extracellular Vesicles Derived From Mesenchymal Stem Cells Macaca fascicularis as a Candidate Cancer Therapeutic Agents.
Article in Journal of medical primatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundExtracellular vesicles (EVs) are membrane vesicles secreted by cells that carry several bioactive molecules, which are currently used in biomedical research as a source of exosomes and to investigate their effect in response to cancer studies.
methodsEVs isolated from the supernatant of Macaca fascicularis Mesenchymal Stem Cells (MSCs), using the commercial ExoQUICK kit, and markers validation evaluated using quantitative reverse transcription Polymerase Chain Reaction (qRT-PCR). EVs were further applied on breast cancer cells (MCF-7) and colorectal cancer cells (WiDr).
resultsThe application of EVs to MCF-7 and WiDr cells showed growth inhibition and resulted in the cells' viability decreased compared to untreated cells. The apoptosis (BAX and BCL2) and proliferation markers (PCNA and P53) on both cells demonstrated increasing than untreated cells, expecting that the EVs prevent the cells' growth uncontrolled.
conclusionThe EVs have the potential to inhibit the growth of cancer and colon cancer in vitro, determining their potential for developing as an anticancer agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.